Table 1 Baseline characteristics.
From: Sympathetic hyperactivity influences chemosensor function in patients with end-stage renal disease
Controls (n = 10) | ESRD (n = 10) | |
|---|---|---|
Age, yr | 62 ± 6 | 65 ± 4 |
Male sex, n | 6 | 6 |
Hx hypertension, n | 7 | 7 |
Hx dyslipidemia, n | 8 | 7 |
Hx smoking, n | 6 | 5 |
Hx CAD, n | 5 | 4 |
Hx CVD, n | 4 | 1 |
Hemoglobin, g/l | 132 ± 7 | 126 ± 4 |
Medication, n (%) | ||
Alpha-blockers | 3 | 1 |
Beta-blockers | 6 | 5 |
ACE-inhibitors/AT-II-antagonists | 6 | 6 |
Calcium antagonists | 5 | 2 |
Central sympatholytic agents | 0 | 2 |
Isosorbide dinitrate | 3 | 1 |
Diuretics | 7 | 5 |
Statins | 7 | 5 |